1. Executive Summary 2. United States Actual Non–Invasive Prenatal Testing Volume (Number of Tests Performed) and Forecast (2015 - 2027) 2.1 Average Risk Actual NIPT Test Volume (Number of Tests Performed) and Forecast 2.2 High-Risk Actual NIPT Test Volume (Number of Tests Performed) and Forecast 3. United States Potential Non–Invasive Prenatal Testing Volume (Number of Tests Performed) and Forecast (2015 - 2027) 3.1 Average Risk Potential NIPT Test Volume (Number of Tests Performed) and Forecast 3.2 High-Risk Potential NIPT Test Volume (Number of Tests Performed) and Forecast 4. United States Actual Non–Invasive Prenatal Testing Market Size and Forecast (2015 - 2027) 4.1 Average Risk Actual NIPT Test Market Size and Forecast 4.2 High-Risk Actual NIPT Test Market Size and Forecast 5. United States Potential Non–Invasive Prenatal Testing Market Size and Forecast (2015 - 2027) 5.1 Average Risk Potential NIPT Test Market Size and Forecast 5.2 High-Risk Potential NIPT Test Market Size and Forecast 6. United States Non–Invasive Prenatal Testing Market Drivers and Inhibitors 6.1 Key Market Drivers 6.2 Key Market Inhibitors 7. Non–Invasive Prenatal Testing Comparative Analysis 8. Reimbursement Environment of the United States Non-Invasive Prenatal Testing 9. Regulation Framework of the United States Non-Invasive Prenatal Testing 10. Major Deals and Agreements in the Non–Invasive Prenatal Testing Market 10.1 Collaboration Deals 10.2 Venture Capital Investment 10.3 Merger and Acquisition 10.4 Exclusive Agreement 10.5 Licensing Agreement 10.6 Distribution Agreement 10.7 Partnership Deals 11. Key Companies Analysis 11.1 Integrated Genetics (LabCorp) 11.1.1 Business Overview 11.1.2 Product Outlook 11.1.3 Key Developments 11.2 Yourgene Health 11.2.1 Business Overview 11.2.2 Product Outlook 11.2.3 Key Developments 11.3 Ariosa Diagnostics (Roche) 11.3.1 Business Overview 11.3.2 Product Outlook 11.3.3 Key Developments 11.4 Illumina 11.4.1 Business Overview 11.4.2 Product Outlook 11.4.3 Key Developments 11.5 Natera 11.5.1 Business Overview 11.5.2 Product Outlook 11.5.3 Key Developments 11.6 Quest Diagnostics 11.6.1 Business Overview 11.6.2 Product Outlook 11.6.3 Key Developments 11.7 Myriad Genetics 11.7.1 Business Overview 11.7.2 Product Outlook 11.7.3 Key Developments 11.8 Centogene 11.8.1 Business Overview 11.8.2 Product Outlook 11.8.3 Key Developments 11.9 Invitae Corporation 11.9.1 Business Overview 11.9.2 Product Outlook 11.9.3 Key Developments 11.10 GenPath 11.10.1 Business Overview 11.10.2 Product Outlook 11.10.3 Key Developments 11.11 Progenity 9.11.1 Business Overview 11.11.1 Product Outlook 11.11.2 Key Developments 11.12 PerkinElmer 11.12.1 Business Overview 11.12.2 Product Outlook 11.12.3 Key Developments 11.13 Agilent Technologies 11.13.1 Business Overview 11.13.2 Product Outlook 11.13.3 Key Developments

List of Tables Table 6–1: Maternal Age at Delivery and Risk of Down Syndrome Table 7–1: Non–Invasive Prenatal Testing – Comparative Tests Analysis Table 10–1: Collaboration Deals in the Non–Invasive Prenatal Testing Market Table 10–2: Venture Capital Investment in the Non–Invasive Prenatal Testing Market Table 10–3: Merger & Acquisition in the Non–Invasive Prenatal Testing Market Table 10–4: Exclusive Agreement in the Non–Invasive Prenatal Testing Market Table 10–5: Licensing Agreement in the Non–Invasive Prenatal Testing Market Table 10–6: Distribution Agreement in the Non–Invasive Prenatal Testing Market Table 10–7: Partnership Deals in the Non–Invasive Prenatal Testing Market List of Figures Figure 2–1: United States Actual NIPT Test Volume (Thousand),2015 – 2019 Figure 2–2: United States Actual NIPT Test Volume Forecast (Thousand),2020 – 2027 Figure 2–3: United States Average Risk Actual NIPT Test Volume (Thousand),2015 – 2019 Figure 2–4: United States Average Risk Actual NIPT Test Volume Forecast (Thousand),2020 – 2027 Figure 2–5: United States High-Risk Actual NIPT Test Volume (Thousand),2015 – 2019 Figure 2–6: United States High-Risk Actual NIPT Test Volume Forecast (Thousand),2020 – 2027 Figure 3–1: United States Potential NIPT Test Volume (Thousand),2015 – 2019 Figure 3–2: United States Potential NIPT Test Volume Forecast (Thousand),2020 – 2027 Figure 3–3: United States Average Risk Potential NIPT Test Volume (Thousand),2015 – 2019 Figure 3–4: United States Average Risk Potential NIPT Test Volume Forecast (Thousand),2020 – 2027 Figure 3–5: United States High-Risk Potential NIPT Test Volume (Thousand),2015 – 2019 Figure 3–6: United States High-Risk Potential NIPT Test Volume Forecast (Thousand),2020 – 2027 Figure 4–1: United States Actual NIPT Test Market Size (Million US$),2015 – 2019 Figure 4–2: United States Actual NIPT Test Market Size Forecast (Million US$),2020 – 2027 Figure 4–3: United States Average Risk Actual NIPT Test Market Size (Million US$),2015 – 2019 Figure 4–4: United States Average Risk Actual NIPT Test Market Size Forecast (Million US$),2020 – 2027 Figure 4–5: United States High-Risk Actual NIPT Test Market Size (Million US$),2015 – 2019 Figure 4–6: United States High-Risk Actual NIPT Test Market Size Forecast (Million US$),2020 – 2027 Figure 5–1: United States Potential NIPT Test Market Size (Million US$),2015 – 2019 Figure 5–2: United States Potential NIPT Test Market Revenue Forecast (Million US$),2020 – 2027 Figure 5–3: United States Average Risk Potential NIPT Test Market Size (Million US$),2015 – 2019 Figure 5–4: United States Average Risk Potential NIPT Test Market Revenue Forecast (Million US$),2020 – 2027 Figure 5–5: United States High-Risk Potential NIPT Test Market Revenue (Million US$),2015 – 2019 Figure 5–6: United States High-Risk Potential NIPT Test Market Revenue Forecast (Million US$),2020 – 2027